Compare CAAP & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAP | INSP |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.8B |
| IPO Year | 2018 | 2018 |
| Metric | CAAP | INSP |
|---|---|---|
| Price | $25.69 | $97.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $24.60 | ★ $137.50 |
| AVG Volume (30 Days) | 165.5K | ★ 2.4M |
| Earning Date | 11-24-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | 1.09 | ★ 1.48 |
| Revenue | ★ $1,872,934,000.00 | $882,622,000.00 |
| Revenue This Year | $3.24 | $14.97 |
| Revenue Next Year | $9.46 | $11.81 |
| P/E Ratio | ★ $23.34 | $65.40 |
| Revenue Growth | ★ 25.19 | 16.81 |
| 52 Week Low | $15.01 | $70.77 |
| 52 Week High | $26.97 | $216.01 |
| Indicator | CAAP | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 61.39 | 39.02 |
| Support Level | $24.97 | $89.94 |
| Resistance Level | $26.25 | $147.03 |
| Average True Range (ATR) | 0.77 | 8.01 |
| MACD | -0.20 | -6.17 |
| Stochastic Oscillator | 40.45 | 13.45 |
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.